Nocturnal haemodialysis is associated with improved vascular smooth muscle cell biology

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3867-3871

  Chan, Christopher T ^a   Lovren, Fina ^b   Pan, Yi ^b   Verma, Subodh ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Apoptosis; Nocturnal haemodialysis; Phosphate; Runx2; Vascular smooth muscle cell

Indexed keywords

CASPASE 3; TRANSCRIPTION FACTOR RUNX2;

ADULT; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CONVENTIONAL HEMODIALYSIS; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; NOCTURNAL HEMODIALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; RENAL DIALYSIS; YOUNG ADULT;

EID: 71049177885     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp495     Document Type: Article

References (42)

1. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-167
2. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63(Suppl 85): 105-110
3. Clarke MC, Figg N, Maguire JJ et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12: 1075-1080
4. Clarke MC, Littlewood TD, Figg N et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-1538
5. Chen NX, O'Neill KD, Duan D et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-1731
6. Chan CT, Harvey PJ, Picton P et al. Short-term blood pressure, no-radrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42: 925-931
7. Chan CT, Floras JS, Miller JA et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239
8. Yuen D, PierratosA,Richardson RMet al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1407-1412
9. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399-1404
10. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volumeKt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
11. Jindal KK, Manuel A, Goldstein MB. Percent reduction in blood urea concentration during hemodialysis (PRU). A simple and accurate method to estimate Kt/V urea. ASAIO Transactions 1987; 33: 286-288
12. Lovren F, Pan Y, Quan A et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008; 295: H1377-H1384
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45
14. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757
15. Wolf SC, Sauter G, Rodemann HP et al. Influence of growth factors on the proliferation of vascular smooth muscle cells isolated from subtotally nephrectomized rats after endothelin or angiotensin II antagonism. Nephrol Dial Transplant 2005; 20: 312-318 (Pubitemid 40276886)
16. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 2005; 18: 401-408
17. Raj DS, Ouwendyk M, Francoeur R et al. beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15: 58-64
18. Stein GS, Lian JB, van Wijnen AJ et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004; 23: 4315-4329
19. Graciolli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 2009; 24: 1416-1421
20. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
21. Moe SM, Duan D, Doehle BP et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63: 1003-1011
22. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912
23. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567
24. Stenvinkel P, Barany P, Heimburger O et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int 2002; (Suppl 80): 103-108
25. Zampetaki A, Zhang Z, Hu Y et al. Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappaB signaling pathways. Am J Physiol Heart Circ Physiol 2005; 288: H2946-H2954
26. Allen AC, Bailey EM, Brenchley PE et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001; 60: 969-973
27. Hiki Y, Odani H, Takahashi M et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59: 1077-1085
28. Novak J, Julian BA, Tomana M et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008; 28: 78-87
29. BarrattJ,Smith AC, Molyneux K et al. Immunopathogenesis of IgAN. Semin Immunopathol 2007; 29: 427-443
30. Kokubo T, Hiki Y, Iwase H et al. Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol 1997; 8: 915-919
31. Coppo R, Amore A, Gianoglio B et al.SerumIgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol 1993; 104: 162-171
32. Novak J, Tomana M, Matousovic K et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005; 67: 504-513
33. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-2868
34. Xu LX, Yan Y, Zhang JJ et al. The glycans deficiencies of macro-molecular IgA1 is a contributory factor of variable pathological phe-notypes of IgA nephropathy. Clin Exp Immunol 2005; 142: 569-575
35. Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Aberrant IgA1 glycosy-lation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1008-1014
36. Barratt J, Bailey EM, Buck KS et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection inIgA nephropathy. Am J Kidney Dis 1999; 33: 1049-1057
37. Smith AC, Molyneux K, Feehally J et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006; 17: 3520-3528
38. Harper SJ, Allen AC, Bene MC et al. Increased dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ hybridization for J chain mRNA. Clin Exp Immunol 1995; 101: 442-448
39. Harper SJ, Pringle JH, Wicks AC et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994; 45: 836-844
40. Batra A, Smith AC, Feehally J et al. T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 2007; 22: 2540-2548
41. Buren M, Yamashita M, Suzuki Y et al. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 2007; 157: 50-55
42. Feehally J, Beattie TJ, Brenchley PE et al. Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int 1986; 30: 924-931